Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Thiosildenafil is a **small-molecule sildenafil analogue** in which sulfur replaces oxygen in the pyrazolopyrimidine core. It is not a legitimate approved or clinically developed pharmaceutical product; rather, it has been reported as an **undeclared adulterant** in sexual-enhancement dietary supplements and related health products. Based on its close structural relationship to sildenafil, thiosildenafil is generally understood to belong to the **phosphodiesterase-5 inhibitor analogue** family and is therefore expected to have PDE5-inhibitory pharmacology, but its human pharmacology, efficacy, toxicology, and safety have not been adequately characterized in formal development programs. It is primarily encountered as a research or analytical reference standard rather than a medicine for human use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thiosildenafil.